{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.2","estimateComment":"Reference level = 70.2 Gy arm","groupDescription":"The original target sample size was 1520 patients with a requirement of 715 deaths to test the hypothesis of overall survival (OS) efficacy of the 79.2 Gy arm. The trial was designed to detect a hazard ratio (HR) of 1.30 (standard/high-dose) with 90% statistical power at a one-sided significance level of 0.025.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.98","pValueComment":"Two-sided test, significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"1.0","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.2","upperLimit":"90.9","value":"88.5"},{"groupId":"OG001","lowerLimit":"85.7","upperLimit":"90.4","value":"88.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"751"},{"groupId":"OG001","value":"748"}],"units":"Participants"}],"description":"Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier Method. Patients last know to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"70.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.","id":"OG000","title":"70.2 Gy"},{"description":"79.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions . All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.","id":"OG001","title":"79.2 Gy"}],"paramType":"NUMBER","populationDescription":"All eligible patients who did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From randomization to date of failure (death) or last follow-up. Analysis occurs after all patients have been potentially followed for 8 years.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}